Research & Development: MP0250 in multiple myeloma: Clinical trial ongoing with dose set at 8mg/kg every 3 weeks in combination with bortezomib/dexamethasone. Durable responses were seen in patients who came from proteasome inhibitor (PI) based pretreatment, suggesting that MP0250 might be capable

Zurich-Schlieren, October 29, 2018.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin ®  therapeutics* to treat serious diseases, today announced that the phase 3 safety and efficacy data of abicipar in patients with neovascular Age-related

Promising initial data from MP0250 combination with bortezomib (Velcade ® ) in phase 2 study in multiple myeloma: Five of eight evaluable patients achieved an objective response with median time of treatment for responding patients of 22.5 weeks. MP0250 combination with osimertinib (Tagrisso ® ) in

Abicipar, the first and only anti-VEGF to maintain stable vision in greater than 91 percent of patients on a fixed 12-week regimen, achieved the primary endpoint of non-inferiority to monthly ranibizumab at week 52 Two pivotal head-to-head trials demonstrate the efficacy of Abicipar 12-week fixed

Zurich-Schlieren, June 21, 2018.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, announced today the appointment of Pamela A. Trail, Ph.D., as Chief Scientific Officer.

MP0250 is evaluated in combination with Velcade/Dexamethasone (VelDex) in relapsed/refractory multiple myeloma (MM) patients Five of eight patients (62.5%) with relapsed/refractory multiple myeloma showed an objective response to MP0250 plus VelDex Median duration on treatment for patients with

Zurich-Schlieren, May 16, 2018.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, announced today that the complete safety and efficacy results of the Phase 1 study of its lead proprietary oncology drug,

Zurich-Schlieren, Apil 21, 2018.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, announced today that preliminary results from the ongoing Phase 2 study of MP0250 with bortezomib and dexamethasone in

Zurich-Schlieren, Apil 18, 2018. At today’s Annual General Meeting of Molecular Partners AG (SIX: MOLN), the shareholders of the company approved all motions proposed by the Board of Directors with a large majority and elected William (Bill) Burns as new Chairman of the Board.

Research & Development: MP0250 in multiple myeloma (MM): Promising initial safety and efficacy data from the ongoing phase 2 study of MP0250 reconfirmed with updated data presented at the European Myeloma Network Meeting  in Turin on April 21 MP0250 in EGFR-mutated Non-Small Cell Lung Cancer (EGFR